Aidoc's First Read, an AI tool that drafts full chest X-ray radiology reports rather than just flagging abnormalities, received FDA Breakthrough Device Designation, signaling a new regulatory path for generative AI in imaging.
VitVio has opened its Vetro 3D computer-vision platform to hospitals nationwide, using ambient cameras and AI to track every movement in the operating room and pinpoint what's actually driving surgical delays and inefficiency.
Hexarad's AI workflow software OptiRad is now live across nine NHS sites in North East England and South Yorkshire, with one early-adopting trust reporting an 18% cut in scan turnaround times and £150,000 in annual savings.
Nvidia's GR00T-H surgical robotics AI model, trained on 778 hours of real operating room data across 35 organizations, is now commercially available, aiming to give device makers a shared foundation for semi-autonomous surgery.
Mayo Clinic's REDMOD AI model found signs of pancreatic cancer on CT scans radiologists had already called normal, detecting 73% of cases a median of 16 months before diagnosis in a nearly 2,000-scan validation study.
Roche agreed to acquire digital pathology firm PathAI for up to $1.05 billion, aiming to fuse AI-based tissue slide analysis with its oncology companion diagnostics to speed and sharpen cancer treatment matching.
Boston University researchers published an antibody-specific AI framework on August 13, 2026, that improved binding-affinity predictions by up to 27% by focusing model training on the six loops responsible for antigen recognition rather than treating antibodies as generic proteins.
Novo Nordisk and AWS announced a sweeping strategic partnership on August 10, 2026, deploying Amazon Bio Discovery and Bedrock AgentCore through a new London co-innovation hub to accelerate drug candidate design, though experts caution clinical trials remain pharma's real bottleneck.
Insilico Medicine's AI-designed lung disease drug rentosertib won FDA Fast Track status in late July and is heading into Phase III, a test case for whether generative AI drug discovery can produce its first real approval.
A new AI model reads a routine biopsy slide and predicts cancer subtype, genetic mutations and survival outcomes across 32 solid tumor types at once, potentially shortcutting the wait for separate genomic testing.